Jade Biosciences, Inc. (JBIO:NASDAQ) closed at $15.34 on November 16, 2026, down 4.99% on the day. The stock trades 45.2% below its 52-week high of $28.00 and 39.7% above its 52-week low of $10.98. Over the past year, it gained 21.2%. Jade Biosciences, Inc. is part of the Health Care sector.
In 252 trading sessions since November 14, 2025, JBIO closed higher on 125 days (50%). Its best day was November 17, 2025 (+17.66%) and its worst was April 29, 2026 (-15.61%). The stock moved 10% or more in a single session 14 times.
Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the cytokine APRIL for immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes two undisclosed antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
Find more stocks like JBIO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.